(Q7157043)

Pazopanib (English)

3 October 2016

C₂₁H₂₃N₇O₂S

1 reference

Pazopanib (English)

19 November 2016

CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N

1 reference

World Health Organisation international non-proprietary name

Pazopanib (English)

19 November 2016

1 reference

14 February 2018

pazopanib (English)

2 references

medical condition treated

pazopanib (English)

3 October 2016

Recommended INN: List 56

publication date

2006

synovial sarcoma

1 reference

renal clear cell carcinoma

2 October 2018

1 reference

2 October 2018

rare urinary tract tumor

1 reference

gastrointestinal stromal tumor

2 October 2018

1 reference

2 October 2018

renal cell carcinoma

1 reference

connective tissue benign neoplasm

2 October 2018

1 reference

2 October 2018

uterus leiomyosarcoma

1 reference

2 October 2018

renal pelvis carcinoma

1 reference

2 October 2018

kidney cancer

1 reference

2 October 2018

uterine sarcoma

1 reference

Food and Drug Administration

2 October 2018

19 October 2009

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/7RN5DR86CK

2 November 2018

reference URL

http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf

significant drug interaction

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

voriconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

bone marrow failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

idelalisib

bone marrow failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fosphenytoin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

famotidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Colony stimulating factor 1 receptor

1 reference

Fibroblast growth factor receptor 1

17 August 2016

1 reference

Fms related receptor tyrosine kinase 1

17 August 2016

1 reference

Fms related receptor tyrosine kinase 4

17 August 2016

1 reference

Kinase insert domain receptor

17 August 2016

1 reference

KIT proto-oncogene, receptor tyrosine kinase

17 August 2016

1 reference

Platelet derived growth factor receptor beta

17 August 2016

1 reference

Australian pregnancy category D

17 August 2016

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

protein kinase inhibitors

1 reference

5 March 2018

PAZOPanib

Institute for Safe Medication Practices

subject named as

pazopanib

1 reference

reference URL

https://www.ismp.org/recommendations/tall-man-letters-list

InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

2 September 2022

Commons category

Pazopanib

0 references

Identifiers

InChI

1 reference

Pazopanib (English)

19 November 2016

2 references

Pazopanib (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

444731-52-6

2 references

pazopanib (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=444731-52-6

9 April 2021

1 reference

Pazopanib (English)

19 November 2016

2 references

Pazopanib (English)

19 November 2016

Reaxys registry number

11646488

1 reference

pazopanib (English)

3 October 2016

mapping relation type

2 references

PAZOPANIB (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

1 reference

PAZOPANIB (English)

19 November 2016

2 references

inferred from InChIKey

splash10-004i-0910000000-fd84ad14c383d8fa623f

1 reference

0 references

HSDB ID

8210

1 reference

Hazardous Substances Data Bank

28 October 2019

Pazopanib (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

World Health Organisation international non-proprietary name numeric ID

Pazopanib (English)

publication date

17 November 2015

8681

1 reference

reference URL

https://mednet-communities.net/inn/db/ViewINN.aspx?i=8681

1 reference

pazopanib (English)

19 November 2016

pazopanib

0 references

0 references

1 reference

pazopanib (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0256144

2 references

based on heuristic

inferred from InChIKey

2 references

pazopanib (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

pazopanib (English)

19 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

Pazopanib (English)

19 January 2016

1 reference

6 April 2020

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

UMLS CUI

C1831796

1 reference